中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere's Proprietary CD122-Targeting Long-Acting Monoclonal Antibody SIM0725 Approved for Clinical Trial in China

November 10, 2026 — Simcere Pharmaceutical Group (02096.HK) announced today that SIM0725, its proprietary long-acting antagonist monoclonal antibody t...

2026-11-12
SIM0709 Approved to Initiate Clinical Studies in Europe, Marking a Key Step in Global Development for Inflammatory Bowel Disease

Shanghai, China, 9 November 2026 – Simcere Pharmaceutical Group Ltd. (“Simcere”) (HKEX: 2096) today announced that SIM0709, a TL1A/IL-23p19 bispecific...

2026-11-09
Simcere Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis

November 6, 2026 — Simcere Pharmaceutical Group (02096) announced today that the New Drug Application (NDA) for zemprocitinib—an orally administered, ...

2026-11-06
Simcere Pharmaceutical Group and Lynk Pharmaceuticals Reach New Collaboration on Zemprocitinib for Dermatology Indications

On November 2, 2026, Simcere Pharmaceutical Group announced a further expansion of its commercialization collaboration with Lynk Pharmaceuticals (Zhej...

2026-11-02
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Terms of UsePrivacy Policy

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2026 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.